Subconjunctival bevacizumab injection for corneal neovascularization

Cornea

Volumn 27, Issue 2, 2008, Pages 142-147

  Bahar, Irit ^a,b   Kaiserman, Igor ^a   McAllum, Penny ^a   Rootman, David ^a   Slomovic, Allan ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Bevacizumab; Corneal neovascularization; VEGF

Indexed keywords

BEVACIZUMAB; DEXAMETHASONE PLUS TOBRAMYCIN; VASCULOTROPIN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CORNEA; CORNEA NEOVASCULARIZATION; CORNEA VASCULARIZATION; DRUG TOLERABILITY; DRUG USE; FEMALE; FOLLOW UP; HUMAN; IMAGE ANALYSIS; MALE; MEDICAL RECORD REVIEW; PAIN; PRIORITY JOURNAL; REGRESSION ANALYSIS; STUDENT T TEST;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CONJUNCTIVA; CORNEA; CORNEAL NEOVASCULARIZATION; FEMALE; HUMANS; INJECTIONS; MALE; MIDDLE AGED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 38549140058     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICO.0b013e318159019f     Document Type: Article

References (45)

1. Coster DJ. Factors affecting the outcome of corneal transplantation. Ann R Coll Surg Engl. 1981;63:91-97.
2. Khodadoust AA. The allograft rejection reaction: the leading cause of late failure of clinical corneal grafts. In: Jones BR eds. Corneal Graft Failure (Ciba Foundation Symposium). Amsterdam: Elsevier; 1973: 151-164.
3. Ferrara N, Leung DW, Phillips HS. Molecular characterization and distribution of vascular endothelial growth factor. In: Muller EE, MacLeod RB, eds. Neuroendocrine Perspectives. New York: Springer-Verlag; 1991;127.
4. Kenyon BM, Voest EE, Chen CC, et al. A model of angiogenesis in the mouse cornea. Invest Ophthalmol Vis Sci. 1996;37:1625-1632.
5. Phillips GD, Stone AM, Jones BD, et al. Vascular endothelial growth factor (rh VEGF165) stimulates direct angiogenesis in the rabbit cornea. In Vivo. 1994;8:961-966.
6. Amano S, Rohan R, Kuroki M, et al. Requirement for vascular endothelial growth factor in wound-and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci. 1998;39:18-22.
7. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480-1487.
8. Battegay EJ. Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J Mol Med. 1995;73:333-346.
9. Breier G, Albrecht U, Sterrer S, et al. Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. Development. 1992;114:521-532.
10. D'Amore PA. Mechanisms of retinal and choroidal neovascularization. Invest Ophthalmol Vis Sci. 1994;35:3974-3979.
11. Miller JW, Adamis AP, Shima DT, et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol. 1994;145:574-584.
12. Pe'er J, Shweiki D, Itin A, et al. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest. 1995;72:638-645.
13. Tolentino MJ, Miller JW, Gragoudas ES, et al. Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch Ophthalmol. 1996;114:964-970.
14. Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci. 2000;41:2514-2522.
15. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
16. Rosenfeld PJ, Schwartz SD, Blumenkranz MS, et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology. 2005;112:1048-1053.
17. Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study. Ophthalmology. 2005;112:1035-1047.
18. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005;36:331-335.
19. Nguyen QD, Shah S, Tatlipinar S, et al. Bevacizumab suppresses choroidal neovascularization caused by pathological myopia. Br J Ophthalmol. 2005;89:1368-1370.
20. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113:363-372.
21. Steinbrook R. The price of sight-ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med. 2006;355:1409-1412.
22. Moshfeghi AA, Rosenfeld PJ, Puliafito CA, et al. Systemic Bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open label clinical study. Ophthalmology. 2006;113:e1-e12.
23. Bashshur ZF, Bazarbachi A, Schakal A, et al. Intravitreal bevacizumab for the management of choroidal neovascularization in age related macular degeneration. Am J Ophthalmol. 2006;142:1-9.
24. Avery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina. 2006;26:352-354.
25. Spaide RF, Fisher YL. Intravitreal Bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina. 2006;26:275-278.
26. Manzano RP, Peyman GA, Khan P, et al. Inhibition of experimental corneal neovascularization by bevacizumab (Avastin). Br J Ophthalmol. 2007;91:804-807.
27. Erdurmus M, Totan Y. Subconjunctival bevacizumab for corneal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2007;245:1577-1579.
28. Crum R, Szabo S, Folkman J. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science. 1985;230:1375-1378.
29. Lepri A, Benelli U, Bernardini N, et al. Effect of low molecular weight heparan sulphate on angiogenesis in the rat cornea after chemical cauterization. J Ocul Pharmacol. 1994;10:273-280.
30. Proia AD, Hirakata A, McInnes JS, et al. The effect of angiostatic steroids and B-Cyclodextrin tetradecasulfate on corneal neovascularization in the rats. Exp Eye Res. 1993;57:693-698.
31. Haynes WL, Proia AD, Klintworth GK. Effects of inhibitors of arachidonic acid metabolism on corneal neovascularization in the rat. Invest Ophthalmol Vis Sci. 1989;30:1588-1593.
32. Verbey NL, van Haeringen NJ, de Jong PT. Modulation of immunogenickeratitis in rabbits by topical administration of inhibitors of lipoxygenase and cyclooxygenase. Curr Eye Res. 1988;7:361-368.
33. Deutsch TA, Hughes WF. Suppressive effects of indomethacin on thermally induced neovascularization of rabbit corneas. Am J Ophthalmol. 1979;87:536-540.
34. Benelli U, Bocci G, Danesi R, et al. The heparan sulfate suleparoide inhibits rat corneal angiogenesis and in vitro neovascularization. Exp Eye Res. 1998;67:133-142.
35. Lipman RM, Epstein RJ, Hendricks RL. Suppression of corneal neovascularization with cyclosporine. Arch Ophthalmol. 1992;110:405-407.
36. Joussen AM, Kruse FE, Volcker HE, et al. Topical application of methotrexate for inhibition of corneal angiogenesis. Graefes Arch Clin Exp Ophthalmol. 1999;237:920-927.
37. D' Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 1994;91:4082-4085.
38. Zheng M, Deshpande S, Lee S, et al. Contribution of vascular endothelial growth factor in the neovascularization process during the pathogenesis of herpetic stromal keratitis. J Virol. 2001;75:9828-9835.
39. Binetruy-Tournaire R, Demangel C, Malavaud B, et al. Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. EMBO J. 2000;19:1525-1533.
40. Cursiefen C, Cao J, Chen L, et al. Inhibition of lymphagiogenesis and hemangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci. 2004;45:2666-2673.
41. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21:60-65.
42. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
43. Fernando NH, Hurwitz HI. Targeted therapy of colorectal cancer: clinical experience with bevacizumab. Oncologist. 2004;9(Suppl 1):11-18.
44. Fung AE, Rosenfeld PJ, Reichel E. The international Bevacizumab safety study: using the internet to assess drug safety worldwide. Br J Ophthalmol. 2006;90:1344-1349.
45. Kiss C, Michels S, Prager F, et al. Evaluation of anterior chamber inflammatory activity in eyes treated with intravitreal bevacizumab. Retina. 2006;26:877-881.